接受术前化疗的I期中级风险威尔姆斯瘤（IR-WT）患者是威尔姆斯瘤（WT）患者中最大的一组，他们的预后非常好。作者对按国际儿科肿瘤学会-WT-2001协议进行术前和术后治疗的I期上皮型（ET-WT）或基质型（ST-WT）WT患者进行了回顾性分析，这些患者来自英国儿童癌症和白血病组和Gesellschaft für Pädiatrische Onkologie und Hämatologie组在相关的WT试验和研究中参加（2001-2020年）。共有880例I期IR-WT患者，其中包括124例ET-WT，156例ST-WT和600例其他IR-WT（oIR-WT）。与oIR-WT患者相比，I期ET-WT或ST-WT患者年龄显著较小，是其所在组中I期WT的较大比例，并且肿瘤对术前化疗的组织学反应较差。I期ET-WT（96.8％±1.8SE）或ST-WT（96.8％±1.6SE）患者的5年无病生存（EFS）率明显优于oIR-WT患者（90.3％±1.3 SE）（分别为p = .014和p = .009）。多元分析表明，当调整年龄和性别时，组织学类型（ET-WT或ST-WT）仍然是EFS的重要因素（分别为p = .032和p = .022）。在两组中，复发率为3.2％，总体生存率为99.2％。结果表明，I期ET-WT或ST-WT可以被视为低风险WT，应考虑省略术后化疗。接受术前治疗的中级风险威尔姆斯瘤（WT）患者是WT患者中最大的一组。本研究报告了I期上皮型（ET-WT）或基质型WT（ST-WT）患者的预后情况。与其他中级风险WT（oIR-WT）患者相比，这些患者年龄显著更小，并且I期案例比例更大。I期ET-WT和ST-WT患者的无病生存明显优于oIR-WT患者。罕见的复发可治愈，导致总生存率为99.2％。 ©2023美国癌症协会。

Patients treated with preoperative chemotherapy with stage I intermediate-risk Wilms tumor (IR-WT) represent the largest group of patients with Wilms tumor (WT), and they have excellent outcomes.The authors performed a retrospective analysis of patients with stage I epithelial (ET-WT) or stromal type WT (ST-WT) treated pre- and postoperatively according to the International Society of Paediatric Oncology-WT-2001 protocol in the UK Children's Cancer and Leukaemia Group and Gesellschaft für Pädiatrische Onkologie und Hämatologie groups' participation in the relevant WT trials and studies (2001-2020).There were 880 patients with stage I IR-WT, including 124 with ET-WT, 156 with ST-WT, and 600 with other IR-WT (oIR-WT). Patients with stage I ET-WT or ST-WT were significantly younger than patients with oIR-WT, represented a large proportion of stage I WTs in their groups, and tumors showed poor histologic response to preoperative chemotherapy. The 5-year event-free survival (EFS) estimates for patients with stage I ET-WT (96.8% ± 1.8 SE) or ST-WT (96.8% ± 1.6 SE) were significantly better than for patients with oIR-WT (90.3% ± 1.3 SE) (p = .014 and p = .009, respectively). A multivariate analysis showed that histologic type (ET-WT or ST-WT) remained a significant factor for EFS when adjusted for age and gender (p = .032 and p = .022, respectively). In both groups, relapses occurred in 3.2% of patients, and the overall survival was 99.2%.The results suggest that stage I ET-WT or ST-WT could be regarded as low-risk WT, for which omission of postoperative chemotherapy should be considered.Patients with pretreated intermediate-risk Wilms tumor (WT) represent the largest group of patients with WT. This study reports the outcomes of patients with stage I epithelial type (ET-WT) or stromal type WT (ST-WT). These patients were significantly younger and had a larger proportion of stage I cases than patients with other intermediate-risk WT (oIR-WT). The event-free survival for patients with stage I ET-WT and ST-WT was significantly better than for patients with oIR-WT. Rare relapses were curable resulting in 99.2% overall survival.© 2023 American Cancer Society.